- Home
- ESAB vs IONS Comparison
ESAB vs IONS Comparison
Compare ESAB & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | IONS |
|---|---|---|
| Founded | 1904 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 12.3B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | ESAB | IONS |
|---|---|---|
| Price | $113.68 | $80.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $140.38 | $82.82 |
| AVG Volume (30 Days) | 471.3K | ★ 1.9M |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,792,325,000.00 | $966,957,000.00 |
| Revenue This Year | $3.25 | $29.72 |
| Revenue Next Year | $8.37 | $0.97 |
| P/E Ratio | $25.55 | ★ N/A |
| Revenue Growth | 1.19 | ★ 20.41 |
| 52 Week Low | $100.17 | $23.95 |
| 52 Week High | $135.84 | $83.61 |
Technical Indicators
Market Signals| Indicator | ESAB | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 55.39 |
| Support Level | $113.75 | $76.70 |
| Resistance Level | $117.37 | $82.09 |
| Average True Range (ATR) | 2.91 | 2.00 |
| MACD | 0.21 | -0.25 |
| Stochastic Oscillator | 62.14 | 54.91 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.